When Optimal Isn T Objective the Pitfalls of Indefinite Claims
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Jacob R. Rosenbaum and Sarah Haj-Maharsi
Akamai Technologies, Inc. v. MediaPointe, Inc.
Before Taranto, Stoll, and Cunningham. Appeal from the United States District Court for the Central District of California.
Summary: The Federal Circuit affirmed a district court’s finding that two patents were invalid for indefiniteness because the patents failed to provide objective boundaries for terms like “optimal” and “best.”
Media Pointe asserted claims from two patents directed to systems for routing streamed media via an “intelligent distribution network” against Akami. Akamai brought suit in the Central District of California, seeking a declaratory judgment of noninfringement of both patents. Media Pointe counterclaimed for infringement and Akamai sought a declaratory judgment of invalidity. The district court held that the claims using the terms “optimal” or “best” were invalid for indefiniteness under 35 U.S.C. §112. The court granted summary judgment of noninfringement for the remaining claims.
On appeal, the Federal Circuit affirmed the district court’s decision in its entirety. With respect to the indefinite terms, the Federal Circuit held that reasoned terms of degree such as “optimal” and “best” require objective boundaries. The Federal Circuit reiterated that a claim term is indefinite if there are multiple methods by which the claim limitation could be met and no guidance as to which one should be used. The Federal Circuit reasoned that although the specification taught certain factors that may be relevant to the analysis of what is “optimal” or “best,” the specification failed to explain which factors ought to be considered or how to balance those factors. The Federal Circuit affirmed the district court's summary judgment of noninfringement for the remaining claims.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…